Up 752% in one year! This roaring ASX AI stock just hit all-time highs on major revenue milestone

US expansion gaining momentum.

Key points
  • This ASX AI company has delivered a stunning return for investors over the past year.
  • The company is commercialising its cloud-based AI-powered solutions used in healthcare.
  • The group's entry into the lucrative US market is now gaining momentum following regulatory approval.

Investors in Artrya Ltd (ASX: AYA) have been on a whirlwind ride in recent months.

Barely one year ago, shares in this ASX AI stock were changing hands at $0.46 apiece.

Today, Artrya shares reached a new all-time high of $4.29 in morning trade before easing back to $3.92 apiece at the time of writing.

This powerful rally represents a staggering 752% return in just twelve months, blowing the broader market out of the water.

For context, the All Ordinaries Index (ASX: XAO) has risen by 4.53% over the same timeframe.

So, what's behind this remarkable performance?

Let's take a closer look at what's driving the heat for this ASX AI stock.

A medical professional uses a tablet showing a digital image of a human body.

Image source: Getty Images

Improving heart disease diagnostics

Founded in 2019, Artrya is a medical technology company commercialising cloud-based AI solutions for heart disease diagnostics.

Its flagship platform, Salix, provides rapid assessment of chest pain across emergency and primary care settings.

Management believes Salix can improve patient outcomes, lower treatment costs, and streamline clinical workflows.

A major catalyst arrived in August when Artrya secured regulatory approval from the US Food and Drug Administration (FDA) for its Salix Coronary Plaque module.

This milestone followed earlier FDA consent for its Salix Coronary Anatomy product.

These formal ticks of approval paved the way for Artrya to pursue entry into the lucrative American market.

Here, the ASX AI stock is targeting a US market opportunity estimated at US$4.4 billion.

And its commercialisation push appears to be gaining traction.

What happened?

Today, Artrya announced it has now achieved its first revenue from the Salix Coronary Plaque module.

More specifically, US-based Tanner Health has commenced commercial use of the module, generating maiden fee-per-scan revenues for Artrya.

Tanner Health is a community-focused healthcare network serving west Georgia and east Alabama with five hospitals and several practices.

The organisation has now activated the module at its primary hospital in Georgia, with a wider roll-out to further hospitals expected soon.

Artrya Co-Founder and Chief Executive Officer, John Konstantopoulos, stated:

We are thrilled to commence the first clinical use of the Salix® Coronary Plaque module at Tanner Health, which has been well supported by our new U.S. Customer Support team. The ease of activation within the Salix® Coronary Anatomy platform has been well received by the clinicians and the back end processes through to billing are also now established. We look forward to growing adoption across the entire Tanner Health network in the near term, which will generate an attractive ongoing fee to Artrya, from each scan they assess.

What else?

Today's news follows another significant step in Artrya's US expansion.

Last week, shares in the ASX AI stock jumped sharply after unveiling a three-year commercial agreement with Northeast Georgia Health System.

This deal carries a minimum value of US$0.3 million, with further fee-per-scan revenue expected from the Coronary Plaque module and, pending FDA clearance, the Salix Coronary Flow module.

Motley Fool contributor Bart Bogacz has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on AI Stocks

Two woman holding a tablet and clipboard examine a server rack in a data centre.
AI Stocks

The AI share sell-off: 3 ASX stocks I'd buy while investors are nervous

Billions are being spent on AI infrastructure, and I think these businesses could benefit as that investment continues.

Read more »

A concerned man looking at his laptop.
AI Stocks

What on Earth is going on with the NEXTDC share price this year?

Shares have gone from crashing to soaring in a matter of weeks. I've been looking at what comes next.

Read more »

Two woman holding a tablet and clipboard examine a server rack in a data centre.
AI Stocks

Would I buy NEXTDC shares after its 50% jump?

Two major data centre operators have made a surprise move involving NEXTDC. Here's why I think investors should pay attention.

Read more »

IT technician works on a laptop in big data centre full of rack servers.
AI Stocks

5 reasons to buy NEXTDC shares this month

The shares have fallen sharply, but I think the company's contracted demand and growth opportunities could reward patient investors.

Read more »

Man looking at his tablet in a data centre.
AI Stocks

Where could Megaport shares be in 12 months?

The company has secured some enormous contracts, and analysts believe there's plenty more growth to come.

Read more »

IT technician and young female intern walking next to sever racks in a data centre while using a laptop.
AI Stocks

Up 10%! Does today's big news make NEXTDC shares a buy?

After last week's enormous sell-off, I look at whether today's announcement could help restore confidence in the business.

Read more »

Engineer in sterile coverall holds microchip.
AI Stocks

Megaport shares have rocketed 171% since April: Are they still a buy?

I think Megaport shares could climb even higher. But by how much?

Read more »

Woman analysing data.
AI Stocks

Are NextDC shares 'incredibly cheap' after the sell-off?

I take a closer look at whether NEXTDC’s discount to asset value has become too large.

Read more »